I-Cordis Receives Sbir Phase Ii Funding To Develop Treatment For Heart Failure With Preserved Ejection Fraction
I-Cordis Receives Sbir Phase Ii Funding To Develop Treatment For Heart Failure With Preserved Ejection Fraction
09/01/22, 12:20 PM
Location
st. louisi-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF).
Company Info
Location
st. louis, missouri, united states
Additional Info
i-Cordis' mission is to bring together physician-scientists, heart failure experts, basic scientists and drug development experts to develop innovative, safe and effective immuno-modulatory molecules to bring relief to patients with heart failure with preserved ejection fraction.